Phase 3 N=77 Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
Duchenne Muscular Dystrophy
Primary: Change From Baseline in Time to Stand (TTSTAND) Velocity — 0.026; 0.013; 0.027; 0.014 rise/s
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,170 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Psoriasis
Primary: Number of Participants With Serious Adverse Events and Non-Serious Adverse Events — 435; 1215 Participants
Phase 3 N=366 Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Motion Sickness
Primary: Prevention of Vomiting Measured by Vomiting Assessment (VA) — 22; 24; 54 Participants
Phase 3 N=375 A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Primary Fibromyalgia
Primary: Newly Emergent Adverse Events — 77; 132 Participants
Phase 3 N=110 A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
Growth Hormone Deficiency in Children
Primary: Height Velocity — 10.5; 11.0 Cm/year (centimeter per year)
Phase 3 N=168 NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Primary: Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 66 — 0.2964; 25.0557 scores on a scale — p=0.00000001
Phase 3 N=1,489 A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
Stroke
Primary: Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1 — 72.7; 70.3 Percentage of participants
Phase 3 N=520 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Mesothelioma
Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months
Phase 3 N=125 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Part 1: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52 — 2.57; 1.92 scores on a scale — p=0.2441
Phase 3 N=397 Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline at Week 48 in Best-Corrected Visual Acuity in Study Eye — 9.9; 10.9 Letters Read — p=0.006
Phase 3 N=47 Vitamin D in Preschoolers With Viral-induced Asthma
Asthma
Primary: Change From Baseline in Serum 25OHD — 4.3; 9.6 nmol/L
Phase 3 N=10 A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure
Hypertension
Primary: Number of Participants Who Experienced At Least One Treatment-Emergent Adverse Event (TEAE) — 9 Participants
Phase 3 N=2,040 Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin
Injury of Radial Artery
Primary: Radial Artery Occlusion — 13; 13; 10; 13 Participants
Phase 3 N=256 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
Schizophrenia · Schizophrenia; Psychosis
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 — -20.6; -12.2 Score on a scale
Phase 3 N=223 Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Observed Cure Rate Against Strongyloides Stercoralis — 73.3; 89.7; 84.4; 82.8 percentage of participants